Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Atossa Therapeutics (YAG) Stock Price & Analysis

YAG Stock Chart & Stats

€1.95-€0.13(-6.25%)
At close: 5:30 PM GMT+1
EUR 1.8EUR 2EUR 2.230 Jul14 Aug25 Aug18 Sep9 Oct
Day’s Range
EUR 1.95 - EUR 1.95
52-Week Range
EUR 1.52 - EUR 11.90
Previous Close
EUR 2.08
Volume
0
Average Volume (3M)
12
Market Cap
EUR 19.33M
Enterprise Value
-EUR 9.01M
Total Cash (Recent Filing)
EUR 26.09M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
1.24
Next Earnings
Nov 16, 2026 (Est.)
EPS Estimate
-0.77
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance Sheet

A debt-free capital structure removes refinancing obligations and interest-rate exposure, giving Atossa greater flexibility while it funds clinical development. This is a meaningful financial advantage for a company without product revenue, although it does not eliminate the need for future equity financing.

Clinical Pipeline Progress

Progress in the EVANGELINE trial and I-SPY2 collaboration demonstrates that Atossa is advancing its lead oncology program through development rather than remaining at an earlier discovery stage. Continued clinical execution can improve the pipeline’s strategic value and support future partnering or approval opportunities.

Multi-Indication Optionality

Expanding (Z)-endoxifen into oncology and rare-disease indications creates multiple potential development paths from the company’s lead molecule. Diversification across indications may increase the number of clinical and regulatory opportunities, reducing reliance on a single breast-cancer outcome over time.

Bears Say

No Commercial Revenue

Atossa has no commercial product revenue, so its operations and clinical programs are not yet supported by recurring business cash inflows. Until a candidate is approved and commercialized, financial progress will remain dependent on financing capacity and the eventual success of regulatory and clinical development.

Worsening Net Losses

The widening net loss indicates that operating costs are increasing faster than any offsetting income, with no product revenue to absorb the expense base. Persistent losses can reduce financial resilience and require additional capital before the pipeline has an opportunity to generate meaningful economic returns.

Increasing Cash Burn

The accelerating operating cash burn raises the amount of capital Atossa may need to sustain research and clinical activities. Greater funding requirements can constrain development choices and increase dilution risk, particularly because the company has no recurring commercial revenue or self-funding operating base.

Atossa Therapeutics News

YAG FAQ

What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was €1.52 and its highest was €11.90 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is €19.33M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s next earnings report is estimated for Nov 16, 2026 (not yet confirmed), which is in 14 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Aug 07, 2026. The company reported -€0.851 earnings per share for the quarter, beating the consensus estimate of -€0.918 by €0.067.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -0.77.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 9,979,298 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -€0.851 in its last earnings report, beating expectations of -€0.918. Following the earnings report the stock price went up 0.99%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Hedge funds hold Atossa Therapeutics shares: the largest hedge-fund position in Atossa Therapeutics is 1,479,068,539 shares, and hedge funds decreased their holdings by 14.1K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology